Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters

British Journal of Pharmacology

Volumn , Issue , 2016, Pages 2657-2668

  Mayer, F P ^a   Wimmer, L ^b   Dillon Carter, O ^c   Partilla, J S ^c   Burchardt, N V ^a   Mihovilovic, M D ^b   Baumann, M H ^c   Sitte, H H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMEPHEDRONE; 4' METHYLMETHCATHINONE; CARRIER PROTEIN; CATHINONE; DIHYDROMEPHEDRONE; DOPAMINE TRANSPORTER; NOR MEPHEDRONE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; EXTRACELLULAR SPACE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

EID: 84981244418     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13547     Document Type: Article

References (65)

1. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: enzymes. Br J Pharmacol 172: 6024–6109.
2. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: transporters. Br J Pharmacol 172: 6110–6202.
3. Archer JR, Dargan PI, Lee HM, Hudson S, Wood DM (2014). Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances. Clin Toxicol (Phila) 52: 160–165.
4. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192–1203.
5. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (2011). In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218–225.
6. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M et al. (2013). Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38: 552–562.
7. Baumann MH, Solis E Jr, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL (2014). Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34: 15150–15158.
8. Baumann MH, Volkow ND (2016). Abuse of new psychoactive substances: threats and solutions. Neuropsychopharmacology 41: 663–665.
9. Chen N, Reith ME (2004). Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential. J Neurochem 89: 750–765.
10. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
11. den Hollander B, Rozov S, Linden AM, Uusi-Oukari M, Ojanpera I, Korpi ER (2013). Long-term cognitive and neurochemical effects of “bath salt” designer drugs methylone and mephedrone. Pharmacol Biochem Behav 103: 501–509.
12. Drug Enforcement Administration DoJ (2011). Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist 76: 65371–65375.
13. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013). Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85: 1803–1815.
14. Green AR, King MV, Shortall SE, Fone KC (2014). The preclinical pharmacology of mephedrone; not just MDMA by another name. Br J Pharmacol 171: 2251–2268.
15. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55: 463–508.
16. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al. (2011). 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530–536.
17. Hilber B, Scholze P, Dorostkar MM, Sandtner W, Holy M, Boehm S et al. (2005). Serotonin-transporter mediated efflux: a pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology 49: 811–819.
18. Hofmaier T, Luf A, Seddik A, Stockner T, Holy M, Freissmuth M et al. (2014). Aminorex, a metabolite of the cocaine adulterant levamisole, exerts amphetamine like actions at monoamine transporters. Neurochem Int 73: 32–41.
19. Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D, Brunt TM (2015). Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend 147: 109–115.
20. Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA et al. (2016). Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats. Eur Neuropsychopharmacol 26: 288–297.
21. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP et al. (2011). Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J 28: 686–689.
22. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F et al. (2011). Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949–1958.
23. Kelly JP (2011). Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 3: 439–453.
24. Khreit OI, Grant MH, Zhang T, Henderson C, Watson DG, Sutcliffe OB (2013). Elucidation of the Phase I and Phase II metabolic pathways of (+/−)-4′-methylmethcathinone (4-MMC) and (+/−)-4′-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC–MS and LC–MS(2). J Pharm Biomed Anal 72: 177–185.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
26. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ et al. (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63: 585–640.
27. Loi B, Corkery JM, Claridge H, Goodair C, Chiappini S, Gimeno Clemente C et al. (2015). Deaths of individuals aged 16-24 years in the UK after using mephedrone. Hum Psychopharmacol 30: 225–232.
28. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22: 231–236.
29. Martinez-Clemente J, Lopez-Arnau R, Carbo M, Pubill D, Camarasa J, Escubedo E (2013). Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology (Berl) 229: 295–306.
30. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
31. Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010). Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography–mass spectrometry. Anal Bioanal Chem 397: 1225–1233.
32. Miksys SL, Tyndale RF (2002). Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27: 406–415.
33. Miller ML, Creehan KM, Angrish D, Barlow DJ, Houseknecht KL, Dickerson TJ et al. (2013). Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend 127: 248–253.
34. Mollenhauer HH, Morre DJ, Rowe LD (1990). Alteration of intracellular traffic by monensin; mechanism, specificity and relationship to toxicity. Biochim Biophys Acta 1031: 225–246.
35. Motbey CP, Karanges E, Li KM, Wilkinson S, Winstock AR, Ramsay J et al. (2012). Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 7: e45473.
36. Paxinos G, Watson C (2007). The rat brain in stereotaxic coordinates, 6th edn. Elsevier: Amsterdam; Boston.
37. Pedersen AJ, Reitzel LA, Johansen SS, Linnet K (2013). In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 5: 430–438.
38. Pifl C, Reither H, Hornykiewicz O (2015). The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter. Eur J Pharmacol 755: 119–126.
39. Pozo OJ, Ibanez M, Sancho JV, Lahoz-Beneytez J, Farre M, Papaseit E et al. (2015). Mass spectrometric evaluation of mephedrone in vivo human metabolism: identification of phase I and phase II metabolites, including a novel succinyl conjugate. Drug Metab Dispos 43: 248–257.
40. Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH et al. (2015). Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147: 1–19.
41. Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23–40.
42. Rothman RB, Katsnelson M, Vu N, Partilla JS, Dersch CM, Blough BE et al. (2002). Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol 447: 51–57.
43. Sandtner W, Stockner T, Hasenhuetl PS, Partilla JS, Seddik A, Zhang YW et al. (2016). Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol Pharmacol 89: 165–175.
44. Schindler CW, Thorndike EB, Blough BE, Tella SR, Goldberg SR, Baumann MH (2014). Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats. Br J Pharmacol 171: 83–91.
45. Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH (2001). Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem 276: 3805–3810.
46. Scholze P, Norregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH (2002). The role of zinc ions in reverse transport mediated by monoamine transporters. J Biol Chem 277: 21505–21513.
47. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH (2000). Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293: 870–878.
48. Shortall SE, Green AR, Swift KM, Fone KC, King MV (2013). Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br J Pharmacol 168: 966–977.
49. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11: 237–245.
50. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J et al. (2013). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168: 458–470.
51. Sitte HH, Freissmuth M (2015). Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36: 41–50.
52. Sitte HH, Hiptmair B, Zwach J, Pifl C, Singer EA, Scholze P (2001). Quantitative analysis of inward and outward transport rates in cells stably expressing the cloned human serotonin transporter: inconsistencies with the hypothesis of facilitated exchange diffusion. Mol Pharmacol 59: 1129–1137.
53. Sitte HH, Scholze P, Schloss P, Pifl C, Singer EA (2000). Characterization of carrier-mediated efflux in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study. J Neurochem 74: 1317–1324.
54. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.
55. Spiller HA, Ryan ML, Weston RG, Jansen J (2011). Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49: 499–505.
56. van Bree JB, de Boer AG, Danhof M, Ginsel LA, Breimer DD (1988). Characterization of an “in vitro” blood–brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 247: 1233–1239.
57. Vardakou I, Pistos C, Spiliopoulou C (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191–195.
58. Venton BJ, Seipel AT, Phillips PE, Wetsel WC, Gitler D, Greengard P et al. (2006). Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 26: 3206–3209.
59. Waterhouse RN (2003). Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5: 376–389.
60. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J (2011). Mephedrone: use, subjective effects and health risks. Addiction 106: 1991–1996.
61. Wood DM, Greene SL, Dargan PI (2011). Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 28: 280–282.
62. Wright MJ Jr, Angrish D, Aarde SM, Barlow DJ, Buczynski MW, Creehan KM et al. (2012). Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague Dawley rats. PLoS One 7: e44652.
63. Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC (2000). Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem 8: 2689–2692.
64. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V et al. (2009). Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738–746.
65. th May 2016)